News – Page 1102 – Endpoints News

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

8 years ago

House committee wants to know a lot more about the cyberattack that damaged Merck

8 years ago

Versartis shares hammered by a PhIII flop as growth hormone flunks key test

8 years ago

Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Nestle plans to ax hundreds of R&D staffers, shutter big dermatology campus

8 years ago

With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII

8 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

8 years ago

Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet

8 years ago

After settling with the SEC, biotech VC Steven Burrill now faces up to 30 years for fraud, tax evasion charges

8 years ago

FDA's Janet Woodcock: the clinical trials system is 'broken'

8 years ago

Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study

8 years ago

Angry Pfizer accuses J&J of violating antitrust laws in safeguarding a megablockbuster franchise

8 years ago

Sanofi's Elias Zerhouni says his R&D group is ready to stand alone — but big M&A and partnerships still loom large

8 years ago

Lightstone crew adds a $250M Fund II with plans to back biotech startups

8 years ago

Tech maven Travis May takes the helm of Roivant's data mining startup

8 years ago

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar

8 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

8 years ago

Troubled Teva turns to risk-sharing team at Nuvelution to gamble on a new PhIII study

8 years ago

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

8 years ago

OncoMed chief Paul Hastings goes on medical leave

8 years ago

Highlighting a major shift at the FDA, regulators put Amicus' once-spurned drug on fast track

8 years ago

With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica and signals an appetite for ...

8 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

8 years ago

First page Previous page 1099 1100 110111021103 1104 1105 Next page Last page